Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7354934B2 · kind B2 · utility
25Cited by
14References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 13, 2005 |
| Grant date | Apr 8, 2008 |
| Priority date | — |
| Expiry date | Dec 13, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D491/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.